1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
The Japan Pharmaceutical Manufacturers Association (JPMA) believes that the scheme of the off-year drug price revision has already served its role and should thus be scrapped, a senior trade group official says. Speaking at a press conference on October 17,…
To read the full story
Related Article
- JPMA Appreciates Growing Calls for Abolition of Off-Year Revisions: Exec
November 15, 2024
ORGANIZATION
- Policy Veterans’ Group Urges Japan to More than Double Minimum Drug Prices
February 21, 2025
- JPMA to Put Japan’s Social Security Spending Cap Up for Discussion: Exec
February 21, 2025
- Create NDA Category Modeled after FDA’s “505(b)(2)” Pathway: JEMA
February 20, 2025
- Generic Rate Tops 80% in All Prefectures for 1st Time in September: Payer
February 14, 2025
- US Lobbies Send Letters of Protest to Japan Embassy over Off-Year Revision, CEA
February 10, 2025
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…